[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ME02442B - Miševi koji ispoljavaju laki lanac hibridnog imunoglobulina sa promenljivim regionom čovjeka - Google Patents

Miševi koji ispoljavaju laki lanac hibridnog imunoglobulina sa promenljivim regionom čovjeka

Info

Publication number
ME02442B
ME02442B MEP-2016-119A MEP11916A ME02442B ME 02442 B ME02442 B ME 02442B ME P11916 A MEP11916 A ME P11916A ME 02442 B ME02442 B ME 02442B
Authority
ME
Montenegro
Prior art keywords
light chain
variable region
human variable
mice expressing
hybrid light
Prior art date
Application number
MEP-2016-119A
Other languages
German (de)
English (en)
French (fr)
Inventor
Lynn Macdonald
Sean Stevens
Cagan Gurer
Andrew J Murphy
Karolina A Hosiawa
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of ME02442B publication Critical patent/ME02442B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Position Input By Displaying (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MEP-2016-119A 2010-06-22 2011-06-22 Miševi koji ispoljavaju laki lanac hibridnog imunoglobulina sa promenljivim regionom čovjeka ME02442B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35731410P 2010-06-22 2010-06-22
US35731710P 2010-06-22 2010-06-22
EP12195716.1A EP2568049B1 (en) 2010-06-22 2011-06-22 Mice expressing an immunoglobulin hybrid light chain with a human variable region

Publications (1)

Publication Number Publication Date
ME02442B true ME02442B (me) 2016-09-20

Family

ID=44509861

Family Applications (5)

Application Number Title Priority Date Filing Date
MEP-2016-132A ME02440B (me) 2010-06-22 2011-06-22 Miševi koji ispoljavaju laki lanac sa ljudskim lambda promenljivim regionom i mišjim konstantnim regionom
MEP-2016-119A ME02442B (me) 2010-06-22 2011-06-22 Miševi koji ispoljavaju laki lanac hibridnog imunoglobulina sa promenljivim regionom čovjeka
MEP-2017-244A ME02902B (me) 2010-06-22 2011-06-22 Transgeni miševi sa modifikovanim lokusom endogenog lambda imunoglobulina
MEP-2016-87A ME02444B (me) 2010-06-22 2011-06-22 Hibridni laki lanac imunoglobulina koji ispouavaju miševi
MEP-2019-128A ME03386B (me) 2010-06-22 2011-06-22 Hibridni laki lanac imunoglobulina koji ispoljavaju miševi

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MEP-2016-132A ME02440B (me) 2010-06-22 2011-06-22 Miševi koji ispoljavaju laki lanac sa ljudskim lambda promenljivim regionom i mišjim konstantnim regionom

Family Applications After (3)

Application Number Title Priority Date Filing Date
MEP-2017-244A ME02902B (me) 2010-06-22 2011-06-22 Transgeni miševi sa modifikovanim lokusom endogenog lambda imunoglobulina
MEP-2016-87A ME02444B (me) 2010-06-22 2011-06-22 Hibridni laki lanac imunoglobulina koji ispouavaju miševi
MEP-2019-128A ME03386B (me) 2010-06-22 2011-06-22 Hibridni laki lanac imunoglobulina koji ispoljavaju miševi

Country Status (31)

Country Link
US (22) US9035128B2 (me)
EP (7) EP2480675B1 (me)
JP (15) JP6009441B2 (me)
KR (16) KR101970944B1 (me)
CN (4) CN104404050B (me)
AU (1) AU2011271046B2 (me)
BR (3) BR112012033248A2 (me)
CA (2) CA2804311C (me)
CY (5) CY1117537T1 (me)
DK (5) DK3034608T3 (me)
ES (5) ES2576928T3 (me)
HK (4) HK1168384A1 (me)
HR (5) HRP20160497T1 (me)
HU (5) HUE044001T2 (me)
IL (12) IL313063A (me)
LT (4) LT2905338T (me)
ME (5) ME02440B (me)
MX (6) MX348942B (me)
MY (6) MY195214A (me)
NO (1) NO2905338T3 (me)
NZ (6) NZ626979A (me)
PL (5) PL2568049T3 (me)
PT (5) PT2480675T (me)
RS (5) RS56589B1 (me)
RU (3) RU2601297C2 (me)
SG (4) SG186390A1 (me)
SI (5) SI2480675T1 (me)
SM (5) SMT201900241T1 (me)
TR (1) TR201905992T4 (me)
WO (2) WO2011163314A1 (me)
ZA (5) ZA201300063B (me)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2739038C (en) 2008-09-30 2020-04-28 Ablexis, Llc Non-human mammals for the production of chimeric antibodies
CN102292445A (zh) 2008-12-18 2011-12-21 伊拉兹马斯大学鹿特丹医学中心 表达人源化抗体的非人转基因动物及其用途
EP2798950B2 (en) 2009-07-08 2023-03-22 Kymab Limited Animal models and therapeutic molecules
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
HUE026229T2 (en) 2010-02-08 2016-06-28 Regeneron Pharma Common light chain mouse
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
DK3248462T3 (da) 2010-03-31 2024-05-06 Ablexis Llc Genmodificering af mus til fremstilling af kimære antifstoffer
AU2011271046B2 (en) 2010-06-22 2015-10-01 Regeneron Pharmaceuticals, Inc. Hybrid light chain mice
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
AU2011286185B2 (en) 2010-07-26 2014-08-14 Trianni, Inc. Transgenic animals and methods of use
SG187673A1 (en) 2010-08-02 2013-03-28 Regeneron Pharma Mice that make binding proteins comprising vl domains
SG10201914002RA (en) 2011-08-05 2020-03-30 Regeneron Pharma Humanized universal light chain mice
EP2758534B1 (en) * 2011-09-19 2020-04-29 Kymab Limited Animals, repertoires & methods for the production of human antibodies
EP3128009B1 (en) 2011-09-19 2020-07-29 Kymab Limited Antibodies, variable domains & chains tailored for human use
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
KR102186822B1 (ko) * 2011-12-20 2020-12-04 리제너론 파마슈티칼스 인코포레이티드 인간화 경쇄 마우스
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
US9301510B2 (en) 2012-03-16 2016-04-05 Regeneron Pharmaceuticals, Inc. Mice that produce antigen-binding proteins with pH-dependent binding characteristics
JP6185978B2 (ja) 2012-03-16 2017-08-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒスチジン操作された軽鎖抗体およびこれを作製するための遺伝子改変された非ヒト動物
CN104302171B (zh) 2012-03-16 2017-05-03 瑞泽恩制药公司 表达ph敏感性免疫球蛋白序列的非人动物
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
JP2015512635A (ja) 2012-03-28 2015-04-30 カイマブ・リミテッド クラススイッチした完全ヒト抗体の発現のためのトランスジェニック非−ヒト脊椎動物
MX355105B (es) 2013-02-20 2018-04-05 Regeneron Pharma Animales no humanos con secuencia de cadena pesada de inmunoglobulina con modificaciones.
SI3501272T1 (sl) * 2013-03-13 2023-05-31 Regeneron Pharmaceuticals, Inc. Miši, ki izražajo omejen repertoar lahke verige imunoglobulina
PL2967012T3 (pl) 2013-03-14 2021-04-19 Erasmus University Medical Center Rotterdam Transgeniczne ssaki inne niż człowiek do wytwarzania przeciwciał
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
PL3046412T3 (pl) * 2013-09-18 2019-11-29 Regeneron Pharma Przekształcone histydyną łańcuchy lekkie przeciwciał i genetycznie zmodyfikowane zwierzęta inne niż człowiek do ich wytwarzania
DE112014004537T5 (de) 2013-10-01 2016-07-21 Kymab Limited Tiermodelle und therapeutische Moleküle
US20170101460A1 (en) * 2014-01-10 2017-04-13 Allermabs Co. Ltd. Transgenic animals capable of producing humanized ige at much higher levels than mouse ige
MX2016012273A (es) 2014-03-21 2017-02-23 Regeneron Pharma Proteinas de union al antigeno vl que presentan diferentes caracteristicas de union.
KR102276752B1 (ko) 2014-03-21 2021-07-13 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
SG10201810507WA (en) 2014-06-06 2018-12-28 Bristol Myers Squibb Co Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
RU2017113134A (ru) 2014-09-19 2018-10-19 Регенерон Фармасьютикалз, Инк. Химерные антигенные рецепторы
AU2015327819B2 (en) 2014-10-03 2021-07-01 Massachusetts Institute Of Technology Antibodies that bind ebola glycoprotein and uses thereof
EP3221363B1 (en) 2014-11-21 2020-05-06 Bristol-Myers Squibb Company Antibodies against cd73 and uses thereof
KR102582807B1 (ko) 2014-12-19 2023-09-26 레제네상스 비.브이. 인간 c6에 결합하는 항체 및 이의 용도
MA40662B1 (fr) 2014-12-23 2020-12-31 Bristol Myers Squibb Co Anticorps contre tigit
EP3254035B1 (de) 2015-02-05 2019-01-30 Basf Se Solarkraftwerk mit einem ersten wärmeträgerkreislauf und einem zweiten wärmeträgerkreislauf
US11111314B2 (en) 2015-03-19 2021-09-07 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
SI3303396T1 (sl) 2015-05-29 2023-01-31 Bristol-Myers Squibb Company Protitelesa proti OX40 in njihova uporaba
AU2016285920A1 (en) 2015-06-29 2018-02-01 Bristol-Myers Squibb Company Antibodies to CD40 with enhanced agonist activity
CN105274116B (zh) * 2015-10-21 2020-09-29 重庆金迈博生物科技有限公司 一种制备人源化抗体的核酸分子及其应用
JP6983776B2 (ja) 2015-11-19 2021-12-17 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company グルココルチコイド誘発腫瘍壊死因子受容体（ｇｉｔｒ）に対する抗体およびその使用
WO2017095939A1 (en) 2015-12-03 2017-06-08 Trianni, Inc. Enhanced immunoglobulin diversity
US11053288B2 (en) 2016-02-04 2021-07-06 Trianni, Inc. Enhanced production of immunoglobulins
KR20230038311A (ko) 2016-03-04 2023-03-17 브리스톨-마이어스 스큅 컴퍼니 항-cd73 항체와의 조합 요법
IL307425A (en) 2016-03-04 2023-12-01 Univ Rockefeller CD40 antibodies with increased agonistic activity
CA3023678A1 (en) 2016-05-09 2017-11-16 Bristol-Myers Squibb Company Tl1a antibodies and uses thereof
EP3457840B1 (en) 2016-05-20 2024-04-10 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide rnas
KR20230156162A (ko) 2016-06-03 2023-11-13 리제너론 파마슈티칼스 인코포레이티드 외인성 말단 데옥시뉴클레오타이드 전달효소를 발현하는 비인간 동물
WO2017214089A1 (en) * 2016-06-06 2017-12-14 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies with human lambda light chains
US10650241B2 (en) * 2016-06-27 2020-05-12 Facebook, Inc. Systems and methods for identifying matching content
US10077306B2 (en) 2016-07-14 2018-09-18 Bristol-Myers Squibb Company Antibodies against TIM3 and uses thereof
US10981976B2 (en) 2016-08-31 2021-04-20 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
PE20191469A1 (es) 2016-10-13 2019-10-16 Massachusetts Inst Technology Anticuerpos que se unen a la proteina de envoltura el virus zika y usos de los mismos
AU2017348743C1 (en) 2016-10-31 2022-03-03 National University Corporation Tottori University Human antibody–producing non-human animal and method for preparing human antibodies using same
HUE052087T2 (hu) * 2016-11-04 2021-04-28 Regeneron Pharma Génmódosított immunglobulin lambda könnyûlánc lókusszal rendelkezõ nem humán élõlények
MX2019009117A (es) 2017-02-17 2019-09-13 Bristol Myers Squibb Co Anticuerpos anti alfa-sinucleina y usos de los mismos.
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
SI3720279T1 (sl) * 2017-12-05 2022-11-30 Regeneron Pharmaceuticals, Inc. Miši, ki imajo spremenjeno lahko verigo imunoglobulina lambda in njihova uporaba
EP3737700A1 (en) 2018-01-12 2020-11-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
PE20210665A1 (es) 2018-03-23 2021-03-31 Bristol Myers Squibb Co Anticuerpos contra mica y/o micb y sus usos
BR112020019026A2 (pt) 2018-03-24 2020-12-29 Regeneron Pharmaceuticals, Inc. Animal não humano geneticamente modificado, métodos para produzir o animal não humano geneticamente modificado, para geração de uma proteína de ligação a antígeno, para obtenção de um ácido nucleico, e, para obtenção de uma célula que expressa um domínio variável de cadeia pesada de imunoglobulina humana e/ou um domínio variável de cadeia leve de imunoglobulina humana, método in vitro de produção de um domínio variável de imunoglobulina humana, ácido nucleico, célula hospedeira, célula isolada, e, domínio variável de cadeia pesada de imunoglobulina humana
CN112105260B (zh) 2018-03-26 2023-04-28 瑞泽恩制药公司 用于测试治疗剂的人源化啮齿动物
KR102480493B1 (ko) * 2018-06-08 2022-12-21 크리스탈 바이오사이언스 주식회사 동일한 경쇄 i을 갖는 다양한 항체를 생산하기 위한 트랜스제닉 동물
MX2020013652A (es) 2018-06-14 2022-04-21 Regeneron Pharma Animales no humanos con capacidad de reordenamiento dh-dh en las secuencias codificantes de la cadena pesada de inmunoglobulina.
WO2020085011A1 (ja) 2018-10-26 2020-04-30 ビークルエナジージャパン株式会社 電池制御装置
NZ777032A (en) 2018-11-16 2024-07-26 Bristol Myers Squibb Co Anti-nkg2a antibodies and uses thereof
MX2021008796A (es) 2019-01-22 2021-11-12 Bristol Myers Squibb Co Anticuerpos contra subunidad alfa il-7r y usos de estos.
AU2020226865A1 (en) 2019-02-22 2021-07-29 Regeneron Pharmaceuticals, Inc. Rodents having genetically modified sodium channels and methods of use thereof
WO2020247623A1 (en) * 2019-06-05 2020-12-10 Regeneron Pharmaceuticals, Inc. Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof
EP3993623B1 (en) * 2019-07-01 2025-02-19 Trianni, Inc. Transgenic rodents and methods of use thereof
JP2023504172A (ja) 2019-12-02 2023-02-01 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ペプチド－ｍｈｃ ｉｉタンパク質構築物およびそれらの使用
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
JP2023541216A (ja) * 2020-06-25 2023-09-29 ヒューマブ カンパニー リミテッド ヘテロ接合型トランスジェニック動物
KR20230066386A (ko) 2020-09-11 2023-05-15 리제너론 파마슈티칼스 인코포레이티드 항원 특이적 항체의 확인 및 제조
US20240065239A1 (en) 2020-12-16 2024-02-29 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
WO2022140219A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
MX2023007583A (es) 2020-12-23 2023-07-07 Regeneron Pharma Metodos para obtener anticuerpos que se unen a proteinas transmembranarias y celulas que los producen.
WO2023199655A1 (ja) 2022-04-13 2023-10-19 日本精工株式会社 軸受装置の状態の検出方法、検出装置、およびプログラム
USD999969S1 (en) * 2022-04-29 2023-09-26 Shenzhen Intellirocks Tech. Co., Ltd. Lamp
WO2024163477A1 (en) 2023-01-31 2024-08-08 University Of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
WO2024229461A2 (en) 2023-05-04 2024-11-07 Novasenta, Inc. Anti-cd161 antibodies and methods of use thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US7041871B1 (en) * 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE269401T1 (de) 1991-04-10 2004-07-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
IL109168A0 (en) * 1993-04-01 1994-06-24 Univ Columbia A retroviral vector capable of transducing the aldehyde dehydrogenase-1 gene and making cells resistant to the chemotherapeutic agent cyclophosphamide and its derivatives and analogs
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
PT1500329E (pt) * 1996-12-03 2012-06-18 Amgen Fremont Inc Anticorpos humanos que se ligam especificamente ao tnf alfa humano
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
RU2262511C2 (ru) * 2000-05-18 2005-10-20 Джапан Тобакко, Инк. Человеческое моноклональное антитело против ailim, костимулирующей молекулы передачи сигнала, и его фармацевтическое применение
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN101940189A (zh) * 2000-11-30 2011-01-12 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
GB0031284D0 (en) * 2000-12-21 2001-01-31 Ks Biomedix Ltd High affinity antibodies
CN1789416B (zh) * 2001-05-11 2011-11-16 协和发酵麒麟株式会社 含人抗体λ轻链基因的人类人工染色体
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
EP2319301B1 (en) 2001-11-30 2017-09-06 Amgen Fremont Inc. Transgenic animals bearing human Ig lambda light chain genes
US20030217171A1 (en) 2002-05-17 2003-11-20 Von Stuermer Wolfgang R. Self-replicating and self-installing software apparatus
CN103205436B (zh) * 2003-07-15 2016-05-25 人类多克隆治疗公司 人源化免疫球蛋白基因座
CN1605628A (zh) * 2003-09-03 2005-04-13 中国疾病预防控制中心病毒病预防控制所 Cho细胞生产的人源抗甲肝病毒基因工程抗体
DK1773885T3 (da) * 2004-08-05 2010-08-16 Genentech Inc Humaniserede anti-c-met-antagonister
DK1802193T3 (da) 2004-10-19 2014-06-10 Regeneron Pharma Fremgangsmåde til frembringelse af en homozygot mus til genetisk modifikation
ATE499385T1 (de) * 2004-12-29 2011-03-15 Yuhan Corp Tumornekrosefaktor-alpha spezifische humanisierte antikörper
EP2505058A1 (en) 2006-03-31 2012-10-03 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
JP2010501165A (ja) * 2006-08-22 2010-01-21 ジーツー インフラメイション プロプライエタリー リミテッド 抗体の作製方法
RU2445318C2 (ru) 2006-10-02 2012-03-20 Ридженерон Фармасьютикалз, Инк. Высокоаффинные антитела человека к рецептору il-4 человека
US7864492B2 (en) 2006-10-31 2011-01-04 Siemens Industry, Inc. Systems and methods for arc fault detection
DE102007045897A1 (de) 2007-09-26 2009-04-09 Carl Zeiss Microimaging Gmbh Verfahren zur mikroskopischen dreidimensionalen Abbildung einer Probe
WO2009129247A2 (en) * 2008-04-14 2009-10-22 Innovative Targeting Solutions Inc. Sequence diversity generation in immunoglobulins
KR20110020860A (ko) 2008-05-23 2011-03-03 알리바 바이오파마수티컬스, 아이엔씨. 유전자 삽입동물에서 단일 ｖｌ 도메인 항체를 생산하는 방법
CA2739038C (en) * 2008-09-30 2020-04-28 Ablexis, Llc Non-human mammals for the production of chimeric antibodies
CN102292445A (zh) * 2008-12-18 2011-12-21 伊拉兹马斯大学鹿特丹医学中心 表达人源化抗体的非人转基因动物及其用途
EP2798950B2 (en) * 2009-07-08 2023-03-22 Kymab Limited Animal models and therapeutic molecules
HUE026229T2 (en) * 2010-02-08 2016-06-28 Regeneron Pharma Common light chain mouse
EP2582230A1 (en) 2010-06-17 2013-04-24 Kymab Limited Animal models and therapeutic molecules
AU2011271046B2 (en) * 2010-06-22 2015-10-01 Regeneron Pharmaceuticals, Inc. Hybrid light chain mice

Also Published As

Publication number Publication date
US9540452B2 (en) 2017-01-10
PT2480675T (pt) 2016-07-11
US9150662B2 (en) 2015-10-06
SG10201504568YA (en) 2015-07-30
EP2480675B1 (en) 2016-04-06
PT2480676E (pt) 2016-06-09
KR102193823B1 (ko) 2020-12-22
EP2480676A1 (en) 2012-08-01
KR102462042B1 (ko) 2022-11-03
EP3456832A1 (en) 2019-03-20
CN103068993A (zh) 2013-04-24
JP2020062061A (ja) 2020-04-23
HRP20190807T1 (hr) 2019-08-23
KR102059909B1 (ko) 2019-12-27
CA2803864A1 (en) 2011-12-29
PL2480675T3 (pl) 2017-03-31
PT2568049T (pt) 2016-07-11
CN103068994B (zh) 2016-01-20
MX347322B (es) 2017-04-21
ZA201404600B (en) 2015-09-30
SG186390A1 (en) 2013-01-30
EP3034608B1 (en) 2019-01-30
US9394373B2 (en) 2016-07-19
NO2905338T3 (me) 2017-12-30
US9029628B2 (en) 2015-05-12
CY1117537T1 (el) 2017-04-26
KR101934852B1 (ko) 2019-01-04
JP6545773B2 (ja) 2019-07-17
US9206262B2 (en) 2015-12-08
ES2576928T3 (es) 2016-07-12
KR20180135997A (ko) 2018-12-21
CA2804311C (en) 2017-09-12
CA2803864C (en) 2017-05-16
JP2019033765A (ja) 2019-03-07
BR112012032991B1 (pt) 2021-08-10
AU2011271046B2 (en) 2015-10-01
KR20210073609A (ko) 2021-06-18
HUE030285T2 (en) 2017-05-29
US20150173332A1 (en) 2015-06-25
NZ707198A (en) 2016-04-29
KR20190049932A (ko) 2019-05-09
KR20210134424A (ko) 2021-11-09
ZA201300063B (en) 2014-09-25
BR112012033248A2 (pt) 2017-11-28
EP2480676B1 (en) 2016-04-06
NZ627119A (en) 2015-05-29
LT2905338T (lt) 2017-12-27
KR20210013376A (ko) 2021-02-03
DK2568049T3 (en) 2016-08-01
KR20130121814A (ko) 2013-11-06
LT2568049T (lt) 2016-10-10
JP2017012204A (ja) 2017-01-19
KR20220150430A (ko) 2022-11-10
JP2016010415A (ja) 2016-01-21
DK3034608T3 (da) 2019-05-06
JP2018023403A (ja) 2018-02-15
KR20200064166A (ko) 2020-06-05
KR101970944B1 (ko) 2019-04-23
US20160057979A1 (en) 2016-03-03
CN103068994A (zh) 2013-04-24
AU2011271043A1 (en) 2013-01-31
ES2570131T3 (es) 2016-05-17
JP6243384B2 (ja) 2017-12-06
RS55037B1 (sr) 2016-12-30
EP2905338A1 (en) 2015-08-12
SMT201600212B (it) 2016-08-31
IL269078B (en) 2021-05-31
IL282872B (en) 2022-04-01
US20160060359A1 (en) 2016-03-03
JP2021061863A (ja) 2021-04-22
MY165287A (en) 2018-03-21
ME02444B (me) 2016-09-20
KR20130027555A (ko) 2013-03-15
CN103068993B (zh) 2016-01-06
MX347318B (es) 2017-04-21
EP2480675A1 (en) 2012-08-01
IL282872A (en) 2021-06-30
IL255179B (en) 2018-06-28
US20240327785A1 (en) 2024-10-03
KR20190073584A (ko) 2019-06-26
IL313063A (en) 2024-07-01
KR20190142436A (ko) 2019-12-26
DK2480676T3 (en) 2016-06-20
US20150320023A1 (en) 2015-11-12
IL255179A0 (en) 2017-12-31
US9844212B2 (en) 2017-12-19
KR20180135996A (ko) 2018-12-21
RU2016119423A3 (me) 2019-11-19
PL2905338T3 (pl) 2018-01-31
HK1226766A1 (zh) 2017-10-06
AU2011271043B2 (en) 2015-10-01
MX2012015298A (es) 2013-05-01
US9206263B2 (en) 2015-12-08
CY1118126T1 (el) 2017-06-28
EP2905338B1 (en) 2017-08-02
US20140137275A1 (en) 2014-05-15
JP5988969B2 (ja) 2016-09-07
KR101975884B1 (ko) 2019-05-10
LT3034608T (lt) 2019-05-27
RU2590594C2 (ru) 2016-07-10
HUE029692T2 (en) 2017-03-28
WO2011163311A1 (en) 2011-12-29
SI2568049T1 (sl) 2016-10-28
IL223720A (en) 2017-05-29
SMT201600213B (it) 2016-08-31
HUE029691T2 (en) 2017-03-28
US20130326647A1 (en) 2013-12-05
US9226484B2 (en) 2016-01-05
MX336344B (es) 2016-01-15
ES2575223T3 (es) 2016-06-27
IL264634B (en) 2019-09-26
EP2905338B8 (en) 2018-01-24
EP2568049A1 (en) 2013-03-13
CY1117692T1 (el) 2017-05-17
JP6009441B2 (ja) 2016-10-19
IL244450A (en) 2017-11-30
IL223719A (en) 2016-10-31
AU2011271043A9 (en) 2015-10-01
ZA201506598B (en) 2017-03-29
TR201905992T4 (tr) 2019-05-21
JP6341972B2 (ja) 2018-06-13
CN104404050A (zh) 2015-03-11
KR102211911B1 (ko) 2021-02-05
RS55042B1 (sr) 2016-12-30
KR20190014578A (ko) 2019-02-12
SG10201504324UA (en) 2015-07-30
HK1170766A1 (zh) 2013-03-08
EP3205726A1 (en) 2017-08-16
ME02440B (me) 2016-09-20
US20150246977A1 (en) 2015-09-03
IL291301B2 (en) 2023-07-01
HK1183321A1 (zh) 2013-12-20
US9334333B2 (en) 2016-05-10
MY195217A (en) 2023-01-11
PL2568049T3 (pl) 2017-03-31
US9163092B2 (en) 2015-10-20
SG186391A1 (en) 2013-01-30
JP2016010417A (ja) 2016-01-21
MY157477A (en) 2016-06-15
IL291301A (en) 2022-05-01
JP2013531501A (ja) 2013-08-08
US20130323790A1 (en) 2013-12-05
MY195214A (en) 2023-01-11
US9206261B2 (en) 2015-12-08
RU2601297C2 (ru) 2016-10-27
EP2568049B1 (en) 2016-04-13
SI2480676T1 (sl) 2016-10-28
SI2905338T1 (sl) 2017-12-29
ES2721749T3 (es) 2019-08-05
HK1168384A1 (zh) 2012-12-28
US9399683B2 (en) 2016-07-26
NZ605758A (en) 2014-08-29
RS54891B1 (sr) 2016-10-31
RS58736B1 (sr) 2019-06-28
MX2022002117A (es) 2022-03-17
SMT201900241T1 (it) 2019-05-10
IL300712B2 (en) 2024-11-01
NZ605751A (en) 2014-10-31
IL247386A (en) 2017-07-31
IL259965A (en) 2018-07-31
US20190153384A1 (en) 2019-05-23
MX348942B (es) 2017-07-04
IL269078A (en) 2019-11-28
JP7236409B2 (ja) 2023-03-09
DK2480675T3 (en) 2016-08-01
US20120070861A1 (en) 2012-03-22
US10266803B2 (en) 2019-04-23
US20180064078A1 (en) 2018-03-08
CN104404050B (zh) 2018-06-08
JP2013532974A (ja) 2013-08-22
JP2022066449A (ja) 2022-04-28
NZ626979A (en) 2015-05-29
LT2480675T (lt) 2016-10-10
HRP20160794T1 (hr) 2016-08-12
MY195212A (en) 2023-01-11
US20150176002A1 (en) 2015-06-25
US20190203171A1 (en) 2019-07-04
DK2905338T3 (da) 2017-11-06
NZ707200A (en) 2016-04-29
HRP20160865T1 (hr) 2016-10-07
US9850462B2 (en) 2017-12-26
IL291301B1 (en) 2023-03-01
KR102266097B1 (ko) 2021-06-18
RU2724736C2 (ru) 2020-06-25
JP6073441B2 (ja) 2017-02-01
KR101945352B1 (ko) 2019-02-07
HRP20171666T1 (hr) 2017-12-15
HUE036597T2 (hu) 2018-07-30
PL2480676T3 (pl) 2016-10-31
JP2017006152A (ja) 2017-01-12
US20170107484A1 (en) 2017-04-20
CY1119478T1 (el) 2018-03-07
ES2646052T3 (es) 2017-12-11
CN104342455A (zh) 2015-02-11
US9035128B2 (en) 2015-05-19
US20200239837A1 (en) 2020-07-30
JP6963542B2 (ja) 2021-11-10
BR112012032991A2 (pt) 2015-10-06
WO2011163314A1 (en) 2011-12-29
PT2905338T (pt) 2017-11-10
US20150173331A1 (en) 2015-06-25
EP3034608A1 (en) 2016-06-22
IL300712A (en) 2023-04-01
US20170258059A1 (en) 2017-09-14
KR102320944B1 (ko) 2021-11-04
RS56589B1 (sr) 2018-02-28
ME03386B (me) 2020-01-20
ZA201300062B (en) 2014-09-25
US20150351371A1 (en) 2015-12-10
CA2804311A1 (en) 2011-12-29
MY194456A (en) 2022-11-30
KR101991234B1 (ko) 2019-06-20
KR20200143511A (ko) 2020-12-23
AU2011271043A8 (en) 2016-01-21
IL300712B1 (en) 2024-07-01
US9012717B2 (en) 2015-04-21
KR102001430B1 (ko) 2019-07-18
JP2023133554A (ja) 2023-09-22
US20150246976A1 (en) 2015-09-03
KR20230036157A (ko) 2023-03-14
KR102506001B1 (ko) 2023-03-07
ZA201404601B (en) 2016-02-24
HRP20160497T1 (hr) 2016-07-15
JP2018201527A (ja) 2018-12-27
PL3034608T3 (pl) 2019-08-30
JP2018201528A (ja) 2018-12-27
KR102118565B1 (ko) 2020-06-03
RU2013102596A (ru) 2014-07-27
US9066502B2 (en) 2015-06-30
JP2020128440A (ja) 2020-08-27
PT3034608T (pt) 2019-05-28
SMT201600229B (me) 2016-08-31
SI2480675T1 (sl) 2016-08-31
US20150089680A1 (en) 2015-03-26
RU2013102595A (ru) 2014-07-27
US9006511B2 (en) 2015-04-14
BR122020013427B1 (pt) 2021-08-03
IL244450A0 (en) 2016-04-21
US20120073004A1 (en) 2012-03-22
CY1122877T1 (el) 2021-05-05
ME02902B (me) 2018-04-20
CN104342455B (zh) 2017-05-31
MX2012015300A (es) 2013-05-01
BR112012032991A8 (pt) 2020-09-29
SI3034608T1 (sl) 2019-06-28
HUE044001T2 (hu) 2019-09-30
IL259965B (en) 2019-02-28
SMT201700506T1 (it) 2018-01-11
AU2011271046A1 (en) 2013-01-31
KR20190014576A (ko) 2019-02-12
RU2016119423A (ru) 2018-11-07

Similar Documents

Publication Publication Date Title
HRP20160865T1 (hr) Miš koji izražava hibridni laki lanac imunoglobulina s humanom varijabilnom regijom
SG11201405058WA (en) Animals expressing human lambda immunoglobulin light chain variable domain
ZA201505835B (en) Mice expressing a limited immunoglobulin light chain reperoire
PL2384180T3 (pl) Powłoka pieluchy
GB2481036B (en) A vehicle light and a vehicle including at least one vehicle light
GB201004506D0 (en) Light snack
PT2384180E (pt) Capa de fralda